Prexasertib, a selective CHK1 inhibitor, was explored as a single agent in a phase II trial (NCT02735980) involving patients with previously treated ES-SCLC, but it did not show favorable activity [51]. This evidence concerns the gene CHEK1 and small cell lung carcinoma.